Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure

Parissis, John; Karavidas, Apostolos; Bistola, Vasiliki; Arapi, Sophia; Paraskevaidis, Ioannis; Farmakis, Dimitrios; Korres, Dimitrios; Filippatos, Gerasimos; Matsakas, Evangelos; Kremastinos, Dimitrios Th.

doi:10.1016/j.atherosclerosis.2007.04.023

Cited by 46 publications

(33 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to its dual mechanism of action, levosimendan is both a calcium sensitizer, hence enhancing myocardial contractility without causing myocyte calcium overload, and a potassium ATP-dependent channel opener, leading to vasodilation, which reduces left ventricular afterload and improves blood flow to vital organs [17]. Clinical trials have shown that levosimendan enhances both systolic and diastolic left and right ventricular performance [1,18,19], improves endothelial function [20], while it may also bear some anti-inflammatory and anti-apoptotic properties [21].…”

Section: Discussionmentioning

confidence: 98%

Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure

Farmakis

Parissis

Bistola

et al. 2010

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure

Farmakis

Parissis

Bistola

et al. 2010

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

“…Potential explanations for these effects relate to levosimendan-mediated, sustained reductions in inflammatory cytokines and apoptotic factors [56,57]. Furthermore, levosimendan treatment decreases oxidative stress, prevents oxidative damage, and improves endothelial function as well as right ventricular function [58][59][60]. Improving of right ventricular function is especially important in AdHF with signs of right ventricular failure since ascites, oedema and liver or kidney dysfunction have an important impact on QoL.…”

Section: Levosimendanmentioning

confidence: 96%

The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations

Nieminen¹,

Dickstein²,

Fonseca³

et al. 2015

International Journal of Cardiology

Self Cite

138

104

View full text Add to dashboard Cite

End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.

show abstract

“…Levosimendan also has global vasodilatory and anti-ischemic properties that are mediated by activation of adenosine triphosphatesensitive potassium channels in mitochondria of vascular smooth muscle cells (61) and by endothelin-1 inhibition (62). The drug increases CO, decreases PVR, and improves regional perfusion, together with a protective effect against endothelial dysfunction by inhibiting expression of soluble adhesion molecules (63). Levosimendan attenuates injuryinduced RV and LV dysfunction and increases regional blood flow and global oxygen transport (64).…”

Section: Treatment Of Acute Rvfmentioning

confidence: 97%

Medical and Surgical Treatment of Acute Right Ventricular Failure

Lahm

McCaslin

Wozniak

et al. 2010

Journal of the American College of Cardiology

166

140

View full text Add to dashboard Cite

Acute right ventricular (RV) failure is a frequent and serious clinical challenge in the intensive care unit. It is usually seen as a consequence of left ventricular failure, pulmonary embolism, pulmonary hypertension, sepsis, acute lung injury or after cardiothoracic surgery. The presence of acute RV failure not only carries substantial morbidity and mortality, but also complicates the use of commonly used treatment strategies in critically ill patients. In contrast to the left ventricle, the RV remains relatively understudied, and investigations of the treatment of isolated RV failure are rare and usually limited to nonrandomized observations. We searched PubMed for papers in the English language by using the search words right ventricle, right ventricular failure, pulmonary hypertension, sepsis, shock, acute lung injury, cardiothoracic surgery, mechanical ventilation, vasopressors, inotropes, and pulmonary vasodilators. These were used in various combinations. We read the abstracts of the relevant titles to confirm their relevance, and the full papers were then extracted. References from extracted papers were checked for any additional relevant papers. This review summarizes the general measures, ventilation strategies, vasoactive substances, and surgical as well as mechanical approaches that are currently used or actively investigated in the treatment of the acutely failing RV.

show abstract

Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure

Cited by 46 publications

References 27 publications

Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure

Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure

The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations

Medical and Surgical Treatment of Acute Right Ventricular Failure

Contact Info

Product

Resources

About